An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30 mg and Mirodenafil 100 mg in Healthy Male Volunteers

Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.

Start Date01 Nov 2014

Sponsor / Collaborator

SK Chemicals Co. Ltd.

NCT02485028 / CompletedPhase 1

An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30mg and Mirodenafil 50mg in Healthy Male Volunteers

Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 50mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.

Start Date01 Oct 2013

Sponsor / Collaborator

SK Chemicals Co. Ltd.

NCT01232010 / CompletedPhase 1

Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients

This study is designed to investigate the effect of renal impairment on the safety and pharmacokinetics of SK3530 in subjects with renal impairment compared to healthy subjects.

Start Date01 Nov 2009

Sponsor / Collaborator

Asan Medical Center

[+1]

100 Clinical Results associated with Mirodenafil

100 Translational Medicine associated with Mirodenafil

100 Patents (Medical) associated with Mirodenafil

Literatures (Medical) associated with Mirodenafil

01 Dec 2022·Alzheimer's research & therapy

Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions

Article

Author: Rhee, Jinseol ; Choung, Jai Jun ; Kang, Byung Woo ; Kim, Fred ; Cho, Joon-Yong ; Kim, SangYun

Abstract:

Background:

Alzheimer’s disease (AD) pathology is associated with complex interactions among multiple factors, involving an intertwined network of various signaling pathways. The polypharmacological approach is an emerging therapeutic strategy that has been proposed to overcome the multifactorial nature of AD by targeting multiple pathophysiological factors including amyloid-β (Aβ) and phosphorylated tau. We evaluated a blood-brain barrier penetrating phosphodiesterase 5 (PDE5) inhibitor, mirodenafil (5-ethyl-2-7-n-propyl-3,5-dihydrro-4H-pyrrolo[3,2-d]pyrimidin-4-one), for its therapeutic effects on AD with polypharmacological properties.

Methods:

To evaluate the potential of mirodenafil as a disease-modifying AD agent, mirodenafil was administered to test its effects on the cognitive behaviors of the APP-C105 AD mouse model using the Morris water maze and passive avoidance tests. To investigate the mechanisms of action that underlie the beneficial disease-modifying effects of mirodenafil, human neuroblastoma SH-SY5Y cells and mouse hippocampal HT-22 cells were used to show mirodenafil-induced alterations associated with the cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase (PKG)/cAMP-responsive element-binding protein (CREB) pathway, apoptotic cell death, tau phosphorylation, amyloidogenesis, the autophagy-lysosome pathway, glucocorticoid receptor (GR) transcriptional activity, and the Wnt/β-catenin signaling.

Results:

Here, mirodenafil is demonstrated to improve cognitive behavior in the APP-C105 mouse model. Mirodenafil not only reduced the Aβ and phosphorylated tau burdens in vivo, but also ameliorated AD pathology induced by Aβ through the modulation of the cGMP/PKG/CREB signaling pathway, glycogen synthase kinase 3β (GSK-3β) activity, GR transcriptional activity, and the Wnt/β-catenin signaling in neuronal cells. Interestingly, homodimerization and nuclear localization of GR were inhibited by mirodenafil, but not by other PDE5 inhibitors. In addition, only mirodenafil reduced the expression levels of the Wnt antagonist Dickkopf-1 (Dkk-1), thus activating the Wnt/β-catenin signaling.

Conclusions:

These findings strongly suggest that the PDE5 inhibitor mirodenafil shows promise as a potential polypharmacological drug candidate for AD treatment, acting on multiple key signaling pathways involved in amyloid deposition, phosphorylated tau burden, the cGMP/PKG/CREB pathway, GSK-3β kinase activity, GR signaling, and the Wnt/β-catenin signaling. Mirodenafil administration to the APP-C105 AD mouse model also improved cognitive behavior, demonstrating the potential of mirodenafil as a polypharmacological AD therapeutic agent.

01 Jan 2022·The world journal of men's healthQ2 · MEDICINE

Efficacy and Safety of Mirodenafil Oro-Dispersible Film in Korean Patients with Erectile Dysfunction: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Phase IV Study

Q2 · MEDICINE

ArticleOA

Author: Lee, Seung Wook ; Moon, Ki Hak ; Moon, Du Geon ; Yang, Dae Yul ; Yang, Sang-Kuk ; Hyun, Jae Seog ; Cho, Kang Su ; Suh, Jun-Kyu ; Park, Jong Kwan ; Lee, Sung Won ; Chung, Woo Sik ; Min, Kweonsik ; Park, Hyun Jun ; Son, Hwancheol ; Park, Kwangsung

PURPOSE:

To investigate the efficacy, safety, and tolerability of oro-dispersible film (ODF) formulation of mirodenafil 50 mg and 100 mg for the treatment of patients with erectile dysfunction (ED) in Korea.

MATERIALS AND METHODS:

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 129 subjects was performed. Subjects were randomized to either placebo or mirodenafil ODF 50 mg or 100 mg to be taken in an "on demand" manner for 8 weeks. The primary efficacy variable was the International Index of Erectile Dysfunction (IIEF)-5 questionnaire. The secondary efficacy variables comprised Sexual Encounter Profile questions 2 and 3 (SEP2 and SEP3), the Global Assessment Question (GAQ), and the Life Satisfaction Checklist (LSC).

RESULTS:

IIEF-5 was significantly increased in all groups after treatment. However, compared to the placebo group, only the mirodenafil ODF 100 mg group showed a significant difference. SEP2 and SEP3 were increased in both mirodenafil groups; however, the increase was not statistically significant for SEP2. In terms of GAQ and LSC, the mirodenafil ODF groups showed significant increases compared with the baseline. Most treatment-associated adverse events were mild and resolved spontaneously.

CONCLUSIONS:

Mirodenafil ODF is an effective and well-tolerated agent for the treatment of patients with ED in Korea.

02 Nov 2021·Animal cells and systemsQ4 · BIOLOGY

Mirodenafil ameliorates skin fibrosis in bleomycin-induced mouse model of systemic sclerosis

Q4 · BIOLOGY

ArticleOA

Author: Song, Byung Wook ; Jeong, Hoim ; Sohn, Dong Hyun ; Han, Seung Jin ; Lee, Beomgu ; Lee, Seung-Geun ; Roh, Jong Seong

Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of the skin and internal organs. Despite the recent advances in the pathogenesis and treatment of SSc, effective therapies for fibrosis caused by SSc have not yet been established. In this study, we investigated the potential role of mirodenafil, a potent phosphodiesterase 5 (PDE5) inhibitor, in the treatment of fibrosis in SSc. We used a bleomycin (BLM)-induced SSc mouse model to mimic the typical features of fibrosis in human SSc and examined the dermal thickness to assess the degree of skin fibrosis after staining with hematoxylin and eosin or Masson's trichrome stains. The effect of mirodenafil on the expression of profibrotic genes was also analyzed by treating fibroblasts with transforming growth factor (TGF)-β and mirodenafil. We showed that mirodenafil ameliorated dermal fibrosis and downregulated the protein levels of fibrosis markers including COL1A1 and α-SMA in the BLM-induced SSc mouse model. Further, using mouse embryonic fibroblasts and human lung fibroblasts, we demonstrated that the expression of collagen and profibrotic genes was reduced by treatment with mirodenafil. Finally, we showed that mirodenafil inhibited TGF-β-induced phosphorylation of Smad2/3 in fibroblasts, which suggested that this drug may ameliorate fibrosis by suppressing the TGF-β/Smad signaling pathway. Our findings suggest that mirodenafil possesses a therapeutic potential for treating fibrosis in SSc.

News (Medical) associated with Mirodenafil

29 Apr 2024

·www.biospace.com

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)

SEONGNAM-SI, South Korea--(BUSINESS WIRE)-- AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer’s disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA) and UK Medicines and Healthcare Products Regulatory Agency (MHRA) on the Clinical Trial Authorisation of POLARIS-AD. The final decision from EMA was completed on April 24th with clinical trial approvals in the following member states: Czech Republic, Denmark, France, Germany, Italy, Spain and The Netherlands. Currently, 1,150 participants are expected to be randomized into the Phase 3 clinical trial across 200 sites globally. POLARIS-AD is a double-blind, randomized, placebo-controlled, multi-center registration trial evaluating the efficacy and safety of AR1001 (Mirodenafil) in treatment of patients with early Alzheimer’s disease (AD) with confirmed amyloid pathology. This trial utilizes the U.S. Food and Drug Administration (FDA) and EMA accepted primary endpoint, Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB), as well as secondary endpoints including Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13), Amsterdam-Instrumental Activities of Daily Living Questionnaire (A-iADL), Geriatric Depression Scale (GDS), Mini-Mental Status Examination (MMSE), in addition to changes in cerebral spinal fluid (CSF) and plasma biomarkers. James Rock, the Chief Clinical Officer of AriBio stated, “Following the acceptance of the POLARIS-AD in the United Kingdom (UK), the expansion into the additional European countries is another milestone for the registration program for AR1001. This acceptance represents the fourth region that will be actively screening and enrolling participants starting from Q2’2024. The company has committed significant resources to expeditiously and efficiently expand the footprint of the phase 3 program into these regions. This coupled with strong interest for alternative treatment options for patients with AD has fueled global interest in AR1001. Operating this study globally makes the asset extremely attractive for worldwide access should efficacy and safety be demonstrated.” About AR1001 AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, demonstrating multiple mechanisms of action for disease modifying effects that may ameliorate the course of AD. About AR1001-ADP3-US01 (POLARIS-AD) AR1001-ADP3-US01 (NCT05531526) is a Phase 3 double-blind, randomized, placebo-controlled, multi-center trial evaluating the efficacy and safety of AR1001 in patients with early Alzheimer’s disease. The details of the clinical trial are available at ClinicalTrials.gov. About AriBio AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. European Medicines Agency (EMA) aligns with the U.S. Food and Drug Administration (FDA) and UK Medicines and Healthcare Products Regulatory Agency (MHRA) on the Clinical Trial Authorisation of POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd. View source version on businesswire.com: Contacts Fred Kim fredkim@aribiousa.com Source: AriBio Co., Ltd. View this news release online at:

Phase 3Phase 2IND

13 Dec 2022

·www.prnewswire.com

Cyclica and SK Chemicals announce co-development agreement to co-develop novel therapeutics

TORONTO and SEONGNAM-SI, South Korea, Dec. 13, 2022 /PRNewswire/ - Cyclica Inc. ("Cyclica"), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and SK Chemicals Co., Ltd. ("SK Chemicals"), a global leader in total healthcare providing diagnostic, therapeutic and prophylactic solutions, today announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Continue Reading SK Chemicals Logo (CNW Group/Cyclica Inc.) Under the collaboration with SK Chemicals, Cyclica will deploy its robust, proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to Cyclica and SK Chemicals. SK Chemicals will be responsible for the preclinical and clinical development and worldwide commercialization of these pharmaceuticals. "This partnership is a tremendous opportunity to create innovative drug therapies across a number of therapeutic areas. Having Cyclica and SK Chemicals join forces will provide both companies with a competitive advantage, allowing for major advances in understanding disease mechanisms and the potential development of new therapeutics for patients'', said Naheed Kurji, Co-Founder, President and CEO of Cyclica. "We believe Cyclica's technology will help SK Chemicals to develop novel therapeutic candidates against difficult biological targets with little information available. We seek to create synergy arising by combining SK Chemicals' organizational excellence and development experience with Cyclica's expertise and know-how," said Yun Ho Kim, Head of the Pharma Business Division at SK Chemicals. "We are thrilled to collaborate with SK Chemicals. This partnership will leverage our respective strengths in creating new therapeutics for patients and while promoting human health," added Dr. Vern De Biasi, PhD, Chief Partnership Officer at Cyclica. About Cyclica As a neo-biotech, Cyclica is efficiently advancing an industry-leading, robust and sustainable drug discovery portfolio focused on CNS, oncology, and auto-immune diseases. Cyclica has built the only generalizable platform across the entire proteome, expanding the target space for low-data targets, including AlphaFold2 structures, PPIs, and mutant oncogenic targets. Cyclica has brought together a diverse and experienced team of biologists, chemists, computer scientists, and business professionals who are collectively passionate about changing the drug discovery paradigm. By exploring the unexplored, and drugging the undrugged, Cyclica strives to impact patient health like never before. For more information about our company, please visit: cyclicarx.com. About SK Chemicals SK Chemicals is a leading company in the fields of chemistry and life science. Since the establishment of Sunkyung Textiles in 1969, SK chemicals has grown through continuous change and innovation into a chemical and life sciences enterprise representing South Korea. SK Chemicals' life sciences business is dominated by pharmaceuticals and biologics and is aimed at providing comprehensive healthcare solutions that cover patient care from diagnosis to treatment and prevention. The company established a competitive product portfolio in the pharmaceutical field with the consecutive launches of MVIX®, an erectile dysfunction treatment, and MVIX S®, a film-type erectile dysfunction treatment. In addition to its first new natural medicine Joins SK Chemicals boasts a diverse line of medicines including the arthritis treatment patch, Trast® and blood circulation improvement agent, Ginexin®. Learn more at . Forward Looking Information This press release contains forward-looking statements and forward-looking information which include, among other things, plans to advance one or more drug discovery programs by Cyclica and SK Chemicals. Such statements and information are based on management's beliefs and assumptions and on information currently available to management, and involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that expressed or implied by these forward-looking statements and information. Although we believe that we have a reasonable basis for each forward-looking statement and forward-looking information contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. We cannot assure you that the forward-looking statements and forward-looking information in this press release will prove to be accurate. SOURCE Cyclica Inc.

22 Jun 2022

·www.prnewswire.com

At 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research

NEW YORK , June 22, 2022 /PRNewswire/ -- As per Zion Market Research study, The global erectile dysfunction drugs market reached nearly USD 3.64 billion in 2021 and is projected to expand with a compound annual growth rate (CAGR) of approximately 6.9 percent over the forecast period to grow by about USD 5.94 billion by 2028. Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports: As per the analysis shared by our research analyst, the Erectile Dysfunction Drugs Market is expected to grow annually at a CAGR of around 6.9 % (2022-2028). Through the primary research, it was established that the Erectile Dysfunction Drugs Market was valued approximately USD 3.64 Billion in 2021 and is projected to reach to roughly USD 5.94 Billion by 2028. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it. Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries. Zion Market Research published the latest report titled as "Erectile Dysfunction Drugs Market By Therapeutics (Existing Drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline Drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, And Melanocortin Activators), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028." into their research database. Erectile Dysfunction Drugs Market : Overview Erectile dysfunction is the incapability to attain and maintain a hard erection for sexual activity. Having problems with erection isn't usually a reason for fear. However, if erectile dysfunction is a long-term condition, it can create stress, lower self-esteem, and lead to marital issues. Problems obtaining or maintaining an erection can be a symptom of a more serious underlying health issue, as well as a possible risk for cardiovascular disease. To treat such conditions several drugs are available on the market that can help to maintain the erection during sexual intercourse. With a change in lifestyle and increased stress conditions need for these drugs is on the rise. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 190 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Erectile Dysfunction Drugs Market : Growth Drivers Growth in embracing poor lifestyle choices may boost the market growth over the forecast period. With the surge in the adoption of a bad lifestyle, diabetes, obesity, and cardiovascular disease are on the rise, which in turn leads to problems like ED as people become older. The present lifestyle of youth in many emerging countries is very stressful resulting in increased alcoholism, smoking, and fast food or ready-to-eat food consumption. Due to these factors, overall health and fitness are getting compromised which in turn increases the chances of ED. Furthermore, as the senior population grows, so does the number of ED patients, which is a significant driver of the global erectile dysfunction drugs market throughout the projection period. Erectile Dysfunction Drugs Market : Restraints Low awareness and side effects associated with erectile dysfunction drugs may hinder the market growth. Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries. This is mainly due to less knowledge about these types of medication, low buying power, and less willingness to adopt such kinds of medications in lifestyle. Furthermore, side effects associated with these drugs such as headache, upset stomach, flushing, nasal congestion, vision problems, dizziness, diarrhea, and rash also contribute to the slow growth of the market. Directly Purchase a Copy of the Report @ Global Erectile Dysfunction Drugs Market : Opportunities Increased pharmaceutical manufacturing in emerging countries is likely to offer better growth opportunities for market expansion. In the last couple of years, major and emerging brands in pharmaceutical industries have increased their investments in emerging countries like India, China, Africa, and major Middle East countries. This has significantly lowered the cost of medicine along with the supply and the distribution of drugs within the countries which is expected to offer significance. Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market. Global Erectile Dysfunction Drugs Market : Challenges An increase in the availability of counterfeit erectile dysfunction medicines poses a major challenge to the market expansion. The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market. Consumers typically choose lower-cost generic erectile dysfunction pills over more expensive blockbuster kinds due to the profitable marketing of counterfeit erectile dysfunction drugs at considerably cheaper prices than either patented or generic pharmaceuticals. Aside from that, when patents on blockbuster pharmaceuticals expire, new generic equivalents are entering the market, generally at inexpensive rates. Global Erectile Dysfunction Drugs Market : Segmentation The global erectile dysfunction market is categorized based on therapeutics and region. By therapeutics, the global erectile dysfunction market is bifurcated into Existing drugs, Tadalafil, Sildenafil Citrate Vardenafil, Udenafil, Stendra/Spedra, Lodenafil Carbonate, Mirodenafil Pipeline drugs, Apomorphine, Alprostadil, Topiglan, Gene Therapy, and Melanocortin Activators. Get More Insight before [email protected] : List of Key Players of Erectile Dysfunction Drugs Market : Eli Lilly & Co. Pfizer Dong-A Pharmaceutical Co. Ltd Bayer AG Meda Pharmaceuticals Vivus Inc. Apricus Biosciences. Key questions answered in this report: What are the growth rate forecast and market size for Erectile Dysfunction Drugs Market ? What are the key driving factors propelling the Erectile Dysfunction Drugs Market forward? What are the most important companies in the Erectile Dysfunction Drugs Market Industry? What segments does the Erectile Dysfunction Drugs Market cover? How can I receive a free copy of the Erectile Dysfunction Drugs Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments May 2020, Metuchen Pharmaceuticals, L.L.C., a privately owned biopharmaceutical aimed at defining, developing, gaining, and commercializing revolutionary therapeutics for male sexual health conditions, and Neurotrope, Inc. ("Neurotrope") officially revealed that the two firms have decided to enter into a concise merger agreement within which Metuchen and Neurotrope, Inc. will unite in an all-stock purchase arising in a newly formed partnership firm ("Petros"). Petros is anticipated to become a Nasdaq-listed corporation specializing in men's health. Regional Dominance: North America is projected to lead the global market over the forecast period. North America is likely to dominate the global erectile dysfunction drugs market. This is mainly due to the expanding senior population and superior healthcare infrastructure, as per a Rural Health Information Center report released in April 2019 stated that there are more than 46 million older persons in the United States, with that figure predicted to climb to about 90 million by 2050. When the last of the baby boom cohorts reach 65, the number of older individuals is predicted to climb by roughly 18 million between 2020 and 2030. Because ED is particularly frequent in men over the age of 40, the rise in the elderly male population is predicted to increase the number of individuals suffering from it. The domination of these countries is due to the availability of numerous ED medicines by OTC and internet outlets. The National Institute of Diabetes and Digestive and Kidney Diseases stated roughly 30 million men in the United States suffer from ED. Furthermore, the United States has the greatest rate of self-reported ED. As a result, rising ED prevalence in the US is likely to fuel market growth throughout the projection period. Global Erectile Dysfunction Drugs Market is segmented as follows: Erectile Dysfunction Drugs Market : By Therapeutics Type Outlook (2022-2028) Existing drugs Tadalafil Sildenafil Citrate Vardenafil Udenafil Stendra/Spedra Lodenafil Carbonate Mirodenafil Pipeline drugs Apomorphine Alprostadil Topiglan Gene Therapy Melanocortin Activators Erectile Dysfunction Drugs Market : By Region Outlook (2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Press Release For Erectile Dysfunction Drugs Market : Browse Other Related Research Reports from Zion Market Research Medical Enzyme Technology Market - Global Industry Analysis : The global Medical Enzyme Technology market accrued earnings worth approximately 4.5(USD Billion) in 2020 and is predicted to gain revenue of about 6.7(USD Billion) by 2028, is set to record a CAGR of nearly 6.2% over the period from 2021 to 2028. Respiratory Virus Infection Drugs Market - Global Industry Analysis : The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028. Animal Drug Compounding Market - Global Industry Analysis : The global Animal Drug Compounding market accrued earnings worth approximately 1.21(USD Billion) in 2020 and is predicted to gain revenue of about 3.31(USD Billion) by 2028, is set to record a CAGR of nearly 6.5% over the period from 2021 to 2028. Browse through Zion Market Research's coverage of the Global Pharmaceutical Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog : | Market Business Insights Logo: SOURCE Zion Market Research

Gene TherapyCollaborateAcquisition

100 Deals associated with Mirodenafil

External Link

KEGG	Wiki	ATC	Drug Bank
-	Mirodenafil	G04BE	DB11792

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erectile Dysfunction	KR	SK Chemicals Co. Ltd.	18 Jul 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 3	KR	SK Chemicals Co. Ltd.	01 Dec 2007
Diabetes Mellitus	Phase 3	KR	SK Chemicals Co. Ltd.	01 Nov 2007
Alzheimer Disease	IND Approval	CN	ARIBIO Co., Ltd.	10 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2018	Not Applicable	Prostatic Hyperplasia	16	Mirodenafil 50mg	wwgpdhvuxp(cjqmyiqmxp) = esvfnxwrmx qvyidxdnmt (htghskncmy ) View more	Positive	01 Apr 2018
				Placebo	chuwxpccuk(mehwbhvhek) = xgbtvziehy lcxicoewab (ikxcarwcqu )
AUA2011	Not Applicable	Erectile dysfunction due to diabetes mellitus	112	Mirodenafil 100 mg	itcsbhecxb(exlquqxnsg) = ruafmstmxh magbwlcakr (mdhnchfmek ) View more	Positive	01 Apr 2011
				Placebo	itcsbhecxb(exlquqxnsg) = ofdzouymyd magbwlcakr (mdhnchfmek ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis